Compositions and methods for the reduction or prevention of hepatic steatosis
AssigneeNuSirt Sciences, Inc.
InventorsMichael Zemel, Antje Bruckbauer
Life of this patent
Estimating the term…
Abstract
Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.
Claims22
A method of reducing non-alcoholic steatohepatitis (NASH) in a subject in need thereof, comprising administering to the subject a composition comprising:
- a) an amount of leucine in the form of a free amino acid and/or metabolite thereof;
- b) an amount of metformin;
- and
- c) an amount of sildenafil;
- wherein the amount of component (a) administered to the subject is about 0.25-3 g/day of leucine in the form of a free amino acid, and/or about 0.2-3 g/day of leucine metabolite;
- wherein the amount of component (b) administered to the subject is about 10-1000 mg/day of metformin;
- wherein the amount of component (c) administered to the subject is about 0.05-100 mg/day of sildenafil;
- and
- wherein components (a), (b), and (c) are co-administered to the subject simultaneously as a single composition or sequentially.
A method of treating non-alcoholic steatohepatitis (NASH) in a subject in need thereof, comprising administering to the subject a composition comprising:
- a. an amount of leucine in the form of a free amino acid and/or metabolite thereof;
- b. an amount of metformin;
- and
- c. an amount of sildenafil;
- wherein the amount of component (a) administered to the subject is about 0.25-3 g/day of leucine in the form of a free amino acid, and/or about 0.2-3 g/day of leucine metabolite;
- wherein the amount of component (b) administered to the subject is about 10-1000 mg/day of metformin;
- wherein the amount of component (c) administered to the subject is about 0.05-100 mg/day of sildenafil;
- and
- wherein components (a), (b), and (c) are co-administered to the subject simultaneously as a single composition or sequentially.
Dependencies are inferred from the claim text.